Back

A study to assess the ability of the HFA-ICOS risk stratification tool to predict cancer therapy-related cardiac dysfunction for patients receiving anthracycline chemotherapy.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular complications in cardio-oncology: risk assessment Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Alex Byrne

Godalming (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
The prognostic significance of Weber and ventilatory CPET classifications in amyloidosis patients
Doctor L. Ortega Aviles (Rochester, US) Doctor S. Santos Patarroyo (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Assessment of poor cardiovascular health metrics and related disparities among cancer patients in the United States: a nationwide analysis of over 1.5 million individuals
Doctor S. Abohashem (Boston, US)
Abstract Slides Video
Presentation thumbnail
Cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma: a prospective study incorporating risk scores, cardiac biomarkers and cardiovascular magnetic resonance imaging
Doctor C. Glen (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Role of liraglutide on cardiotoxicity and gut microbiota changes induced by doxorubicin in rats
Doctor C. Rodrigues Tonon (Botucatu, BR)
Abstract Slides Video
Presentation thumbnail
Real-world analysis of transcatheter aortic valve replacement in patients with prostate cancer and severe aortic stenosis
Doctor R. Belo Nunes (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular complications in cardio-oncology: risk assessment

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Echocardiographic variables may improve baseline risk prediction of cancer therapy related cardiac dysfunction
thumbnail
Congress Presentation
Current challenges in risk stratification of cancer therapy-related cardiovascular toxicity
thumbnail
Congress Presentation
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources